NEW YORK (GenomeWeb News) – Rosetta Genomics' stock soared 72 percent in mid-afternoon trading on Nasdaq after announcing a successful clinical study on one of its lung cancer diagnostic tests.

The Rehovot, Israel-based company's share price rose $1.33 to $3.18 from yesterday's close of $1.85.

A joint study by the company and Johns Hopkins University showed that the firm's miRview squamous non-small cell lung cancer diagnostic accurately classified NSCLC samples from resection and from fine-needle aspirate cell blocks, Rosetta said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.